NCT04703686已完成2 期
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation19 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2021年3月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 67
- 试验地点
- 19
- 主要终点
- Overall Survival
研究概览
简要总结
This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy:
- cohort 1: DLBCL patients
- cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central review allowing inclusion in this trial.
Patients enrolled will then receive a pre-phase of obinutuzumab followed by experimental treatment:11 cycle of glofitamab.
The primary objective of the study is to assess the anti-lymphoma activity of glofitamab, a bispecific CD3xCD20 monoclonal antibody in patients with relapse/refractory DLBCL (cohort 1) disease after anti-CD19 CAR T-cells therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who received CAR T-cells therapy for R/R DLBCL (cohort 1) or R/R PMBL, mantle cell lymphoma, t-iNHL or iNHL (cohort 2), at least 1 month ago
- •Patients who are not, at least in partial metabolic response from 1 month after CAR T-cells infusion (i.e no metabolic response or first metabolic progressive disease or first relapse from 1 month after CAR T-cells infusion)
- •First metabolic progression, first relapse or no metabolic response after CAR T-cells infusion must be confirmed by PET-CT central review for enrollment
- •DLBCL with demonstrated lymphoma cells-expressing CD20 at relapse post CAR T-cells as demonstrated by biopsy before enrollment (cohort 1 only)
- •Aged 18 years or more with no upper age limit
- •ECOG performance status 0 or 1
- •Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan, or PET-CT with at least one hypermetabolic lesion
- •No persistant CAR-T neurotoxicity symptoms or previous experience during CAR T-cells therapy of neurotoxicity grade > 3
- •Adverse events from prior anti-cancer therapy must have resolved to Grade ≤ 1 (hematological toxicities excepted)
- •Adequate liver function: Total bilirubin ≤ 1.5 x ULN; Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x ULN Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible)
- •Adequate hematological function: Neutrophil count of ≥ 1.0 G/L; Platelet count of ≥ 50 G/L (and platelet transfusion free within 14 days prior to administration of obinutuzumab); Hemoglobin (Hb) ≥ 8.0 g/dL (transfusion free within 21 days prior to administration of obinutuzumab) Note: patients who do not meet the above hematologic criteria, due to extensive tumor involvement in the marrow may be enrolled into the trial after the demonstration of involvement and consultation with the LYSARC. Please consult the LYSARC on the need for transfusion support within 21 days of obinutuzumab
- •Adequate renal function: creatinine clearance (CrCl) calculated by MDRD/cockcroft -Gault formula of ≥ 30 mL/min
- •Negative serum or urinary pregnancy test within 7 days prior to study treatment in women of childbearing potential
- •Negative serologic or PCR test results for acute or chronic HBV infection Note: Patients whose HBV infection status cannot be determined by serologic test results must be negative for HBV by PCR to be eligible for study participation
- •Negative test results for HCV and HIV Note: Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation
- •Patients must agree to either remain completely abstinent or to use two effective contraceptive methods* until:
- •If the patient is a male: at least 3 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer, Men must refrain from donating sperm during this same period
- •If patient is a female of childbearing potential: until at least 18 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer
- •Patient must be willing and able to comply with protocol-mandated hospitalization upon administration of the first dose of glofitamab. Patient must also be willing to comply with all study-related procedures.
- •Signed written informed consent
- •Life expectancy ≥ 3 months
- •Patient covered by any social security system
- •Patient who understands and speaks one of the country official languages
排除标准
- •Previously known CD20 negative status, excepted if a new biopsy for cohort 1 or biopsy or cytometry analysis for cohort 2 proving a CD20 positive status is available before enrollment
- •Patients with CLL, Richter and Burkitt lymphoma
- •Patients relapsing or progressing within 1 months (30 days) after CAR T-cells therapy
- •History of treatment-emergent immune-related adverse events associated with prior immunotherapeutic agents, as follows:
- •Grade ≥ 3 adverse events with the exception of Grade 3 endocrinopathy managed with replacement therapy
- •Grade 1-2 adverse events that did not resolve to baseline after treatment discontinuation
- •Current or past history of detectable cerebrospinal fluid lymphoma cells, or with a history of CNS lymphoma localization or primary CNS lymphoma
- •Current or past history of cerebral disorders
- •Any serious psychiatric illness that would prevent the subject from signing the informed consent form.
- •Patients with history of macrophage activation syndrome (MAS) / hemophagocytic lymphohistiocytosis (HLH)
- •Patients with known acute infection or reactivation of a latent infection, whether bacterial, viral (including, but not limited to, EBV, cytomegalovirus (CMV), hepatitis B, hepatitis C, and HIV), fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) in 2 week prior to enrollment
- •LVEF < 40% as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan or significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina)
- •Any serious active disease or co-morbid medical condition
- •Clinically significant history of liver disease or cirrhosis
- •Prior history of malignancies other than lymphoma unless the subject has been free of the disease for ≥ 3 years. Exceptions will be allowed for patients with non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or any surgically removed stage 0 (in situ) carcinoma
- •Prior solid organ transplantation
- •Prior allogeneic SCT
- •Autologous SCT within 100 days prior to obinutuzumab infusion
- •Current uncontrolled autoimmune disease Note: History of autoimmune disease currently controlled and stable is acceptable for such therapy. See detailed description below*
- •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
- •Major surgery or significant traumatic injury < 28 days prior to the obinutuzumab infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment
- •Administration of a live, attenuated vaccine within 4 weeks before obinutuzumab infusion
- •Treatment between infusion of CAR T-cells and pre-phase (i.e. obinutuzumab infusion on C1/D-3): with standard radiotherapy, systemic immunotherapeutic agents, any chemotherapeutic agent, any systemic immunosuppressive medications or treatment with any other investigational anti-cancer agent (defined as treatment for which there is currently no regulatory authority approved indication) Note: with the exception of corticosteroid treatment < 25 mg/day prednisone or equivalent. Inhaled and topical steroids are permitted
- •Patient with history of confirmed progressive multifocal leukoencephalopathy (PML)
- •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
- •History of illicit drug or alcohol abuse within 12 months prior to enrollment
- •Person deprived of his/her liberty by a judicial or administrative decision
- •Inability to comply with protocol mandated hospitalization and restrictions
- •Adult person under legal protection
- •Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
- •Pregnant or breast-feeding or intending to become pregnant during the study
研究组 & 干预措施
Obinutuzumab + RO7082859
Experimental
干预措施: Obinutuzumab (Drug)
Obinutuzumab + RO7082859
Experimental
干预措施: RO7082859 (Drug)
结局指标
主要结局
Overall Survival
时间窗: 4 years
Overall survival will be measured from the date of C1D1 of glofitamab to the date of death from any cause. Alive patients will be censored at the date of last contact
次要结局
- Best metabolic response assessed by local review(after 11 cycles (1st cycle of 14 days and subsequent cycles of 21 days))
- number of Serious Adverse Events(from the date of first informed consent signature to 30 days after last administration of study drugs)
- Quality of Life - QLQ-C30(At cycle 5 day 1 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life - EORTC QLQ-C30(At Cycle 3 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Metabolic response rates according to Lugano classification(At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life - FACT-Lym LymS(At Cycle 2 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days))
- Duration of Response (DoR)(At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 11 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ FACT-Lym LymS(At Cycle 11 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ QLQ-C30(At Cycle 11 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Best metabolic response assessed by central review(after 11 cycles (1st cycle of 14 days and subsequent cycles of 21 days))
- Metabolic response rates according to Lugano classification(At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days))
- Metabolic response rates according to Lugano classification(At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days))
- Metabolic response rates according to Lugano classification(At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 4 (1st cycle of 14 days and subsequent cycles of 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days))
- Progression Free Survival (PFS)(At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days))
- Duration of Response (DoR)(At the end of Cycle 2 (1st cycle of 14 days and subsequent cycles of 21 days))
- Duration of Response (DoR)(At the end of Cycle 4 (1st cycle of 14 days and subsequent cycles of 21 days))
- Duration of Response (DoR)(At the end of Cycle 6 (1st cycle of 14 days and subsequent cycles of 21 days))
- Duration of Response (DoR)(At the end of Cycle 9 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life - QLQ-C30(at day 1)
- Quality of Life - FACT-Lym LymS(at day 1)
- Quality of Life - QLQ-C30(At Cycle 2 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ FACT-Lym LymS(At Cycle 3 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ FACT-Lym LymS(At cycle 5 day 1 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ QLQ-C30(At Cycle 7 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ FACT-Lym LymS(At Cycle 7 Day 1 (1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ QLQ-C30(At Cycle 9 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
- Quality of Life _ FACT-Lym LymS(At Cycle 9 Day 1(1st cycle of 14 days and subsequent cycles of 21 days))
研究者
研究点 (19)
Loading locations...
相似试验
进行中（未招募）
2 期
Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell TherapyDiffuse Large B Cell LymphomaNCT06552572Samsung Medical Center30
进行中（未招募）
1 期
STUDY EVALUATING EFFECTIVNESS of ANTICD20XCD3 BISPECIFIC ANTIBODIES FOR RELAPSE/REFRACTORY LYMPHOMAS AFTER CART THERAPYEUCTR2020-001985-12-FRYSARC78
撤回
2 期
A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell LymphomaB-cell LymphomaNCT06670105M.D. Anderson Cancer Center30
招募中
2 期
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaMantle Cell LymphomaNCT06252675University of California, San Francisco30
进行中（未招募）
2 期
GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaRelapsed/refractory Diffuse Large B Cell LymphomaNCT05335018Seoul National University Hospital76